Orchid Pharma Limited — Credit Ratings, 07-08-2025: Credit Rating

Orchid Pharma's credit ratings, including `CARE A- (RWD)` for long-term facilities of ₹207.50 Cr and `CARE A2 (RWD)` for short-term facilities of ₹84.00 Cr, have been reaffirmed and continue to be on Rating Watch with Developing Implications by CARE Ratings. This decision considers the company's FY25 operational and financial performance, the proposed amalgamation with Dhanuka Laboratories, and the acquisition of Allecra Therapeutics assets. The continued 'Rating Watch' indicates CARE will reassess the credit profile once the full impact of these developments is clear. For investors, this signals a period of uncertainty, as future borrowing costs and market confidence will hinge on the resolution of these strategic initiatives and their ultimate effect on the company's financial health.